Why did Plamen Tonchev part ways with DANS? Dimitar Stoyanov to FACTI (VIDEO)

If we look globally at the events of the last few days - I mean the change of job of the head of DANS Plamen Tonchev, who went to the Commission on Files in the middle of his mandate, and the “return“ of Dzhevdzhet Chakarov to the DPS, the things are connected to Peevski. The connection that is based is with the person Delyan Slavchev Peevski. Denyo Denev was chosen as the interim acting head of DANS. He is an employee who is from Karnobat, passes through the Burgas office and is said to be extremely close to Peevski. If we say that the change of job of Plamen Tochev is a matter of a deal, then it is between Rumen Radev and Delyan Peevski. Tonchev was the last head of a law enforcement agency to be appointed during Radev's caretaker governments. Tonchev is Radev's choice. Tonchev is a former head of BOPA, then he moved to intelligence, but I can't say I have particularly positive impressions of his work. Tonchev was another chairman of the National Security Agency who does nothing. This was announced to Lili Marinkova in the studio “FACTS“ and the show “Conversation“ by journalist Dimitar Stoyanov from the website “Bird bg“.

“There is an investigation that Tonchev's reshuffle may be related to his son, who is involved in the Bulgarian market of oncology drugs. In Bulgaria, there is one supplier who is almost a monopolist of a drug that has been deregistered from the positive list. The problem is the following. This deregistration from the positive list is taking place at the request of the deputy governor of the National Health Insurance Fund, Prof. Mavrov. Thus, the prices at which these medications are sold, and we have established it, are twice the ceiling of the market price at which the product is offered. The medicine is used for a certain range of diseases and so some hospitals buy it at double the price. It is clear that behind this obvious vicious practice are corrupt deals. And the son of the former director of SANS Plamen Tonchev is a partner in a third company with the owner of the company, which is a monopolist supplier of these drugs for rare diseases. The scale of the trade is enormous, because public procurement is not launched, but is awarded on the basis of framework contracts, because some of these drugs have a European license, but in our country the national licensing procedure has not been completed“, the journalist also shared.

See more of the conversation in the VIDEO.